Selected article for: "cross neutralizing activity and neutralizing activity"

Author: Chunyun Sun; Long Chen; Ji Yang; Chunxia Luo; Yanjing Zhang; Jing Li; Jiahui Yang; Jie Zhang; Liangzhi Xie
Title: SARS-CoV-2 and SARS-CoV Spike-RBD Structure and Receptor Binding Comparison and Potential Implications on Neutralizing Antibody and Vaccine Development
  • Document date: 2020_2_20
  • ID: nhq0oq8y_23
    Snippet: Interestingly, three ACE2-non-blocking monoclonal antibodies showed modest binding activities to SARS-CoV S1 protein (EC 50 >100ng/mL) and neutralizing activities to the SARS-CoV PSV (minimum dose to reach 100% neutralization at ≥ 10 μg/mL). Although, these nAbs were less potent than the ACE2-blocking nAbs to SARS-CoV, but could evidently cross-bind to the SARS-CoV-2 S1 protein (EC 50 <3μg/mL) and cross-neutralize SARS-CoV-2 PSV (>50% neutral.....
    Document: Interestingly, three ACE2-non-blocking monoclonal antibodies showed modest binding activities to SARS-CoV S1 protein (EC 50 >100ng/mL) and neutralizing activities to the SARS-CoV PSV (minimum dose to reach 100% neutralization at ≥ 10 μg/mL). Although, these nAbs were less potent than the ACE2-blocking nAbs to SARS-CoV, but could evidently cross-bind to the SARS-CoV-2 S1 protein (EC 50 <3μg/mL) and cross-neutralize SARS-CoV-2 PSV (>50% neutralizing activity at 100μg/mL) ( Table 2) . RP01: polyclonal antibody from rabbit immunized with SARS-CoV S1 protein.

    Search related documents:
    Co phrase search for related documents